Taiane Schneider

Taiane Schneider

Auto-generated profile, based on publicly available information

Taiane Schneider

Universidade Regional Integrada do Alto Uruguai e das Missões

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2016 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
SSSusana Sánchez-Tena
Susana Sánchez-Tena
MCMonica Cubillos-Rojas
Monica Cubillos-Rojas
TSTaiane Schneider
Taiane Schneider
Jose Luis RosaJose Luis Rosa
Jose Luis Rosa

8 July 2015 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
LNLam Son Nguyen
Lam Son Nguyen
TSTaiane Schneider
Taiane Schneider
MRMarlène Rio
Marlène Rio
SMSébastien Moutton
Sébastien Moutton
KSKarine Siquier-Pernet
Karine Siquier-Pernet
LCLaurence Colleaux
Laurence Colleaux
Megalencephaly is a congenital condition characterized by severe overdeveloped brain size. This phenotype is often caused by mutations affecting the RTK/PI3K/mTOR (receptor tyrosine kinase-phosphatidylinositol-3-kinase-AKT) signaling and its downstream pathway of mammalian target of rapamycin (mTOR). Here, using a whole-exome sequencing in a Moroccan consanguineous family, we show that a novel autosomal-recessive neurological condition characterized by megalencephaly, thick corpus callosum and severe intellectual disability is caused by a homozygous nonsense variant in the HERC1 gene. Assessment of the primary skin fibroblast from the proband revealed complete absence of the HERC1 protein. HERC1 is an ubiquitin ligase that interacts with tuberous sclerosis complex 2, an upstream negative regulator of the mTOR pathway. Our data further emphasize the role of the mTOR pathway in the regulation of brain development and the power of next-generation sequencing technique in elucidating the genetic etiology of autosomal-recessive disorders and suggest that HERC1 defect might be a novel cause of autosomal-recessive syndromic megalencephaly.

1 March 2012 in Journal of Invertebrate Pathology
Verified
Journal Article
Closed access
Roberto Christ Vianna SantosRoberto Christ Vianna Santos
Roberto Christ Vianna Santos
CACamilla Filippi dos Santos Alves
Camilla Filippi dos Santos Alves
TSTaiane Schneider
Taiane Schneider
LLLeonardo Quintana Soares Lopes
Leonardo Quintana Soares Lopes
CACarlos Aurich
Carlos Aurich
RVRodrigo de Almeida Vaucher
Rodrigo de Almeida Vaucher

31 July 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
TSTaiane Schneider
Taiane Schneider
AMArturo Martinez-Martinez
Arturo Martinez-Martinez
MCMonica Cubillos-Rojas
Monica Cubillos-Rojas
RBRamon Bartrons
Ramon Bartrons
FVFrancesc Ventura
Francesc Ventura
Jose Luis RosaJose Luis Rosa
Jose Luis Rosa
The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation

12 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MCMonica Cubillos-Rojas
Monica Cubillos-Rojas
TSTaiane Schneider
Taiane Schneider
OHOuadah Hadjebi
Ouadah Hadjebi
LPLeonardo Pedrazza
Leonardo Pedrazza
JOJarbas Rodrigues de Oliveira
Jarbas Rodrigues de Oliveira
Jose Luis RosaJose Luis Rosa
Jose Luis Rosa
The HERC2 ubiquitin ligase is essential for embryonic development and regulates motor coordination

20 April 2017 in Nutrition and Cancer
Verified
Journal Article
Closed access
FCFrancine C. Cadoná
Francine C. Cadoná
Jose Luis RosaJose Luis Rosa
Jose Luis Rosa
TSTaiane Schneider
Taiane Schneider
MCMonica Cubillos-Rojas
Monica Cubillos-Rojas
SSSusana Sánchez-Tena
Susana Sánchez-Tena
ICIvana Beatrice Beatrice Mânica Mânica Da Cruz
Ivana Beatrice Beatrice Mânica Mânica Da Cruz
The mammalian target of rapamycin (mTOR) and mitogen-activated protein kinases (MAPKs) pathways are frequently upregulated in cancer. Some authors have reported that some antioxidant molecules could be potential inhibitors of these pathways. Therefore, we investigated the in vitro antitumor effect of guaraná by inhibiting the AKT/mTOR/S6K and MAPKs pathways. Colorectal and breast cancer cell lineages, HT-29 and MCF-7 cells, respectively, were exposed to different guaraná concentrations (0.1, 1, 10, and 100 µg/mL) as well as its main bioactive molecule, caffeine, in proportional concentrations to those found in the extract. Western blot, clonogenic assay, and growth curve were performed. Moreover, we investigated the potential cytotoxic effect of guaraná in normal cells. The results revealed that guaraná and caffeine inhibited some MAPKs proteins (p-p38 and p-HSP27) in MCF-7 cells. However, they did not affect this pathway in HT-29 cells. Furthermore, guaraná inhibited mTORC1 (p-S6K) and mTORC2 (p-AKT) in MCF-7 cells, but only mTORC1 in HT-29 cells. Caffeine only inhibited the mTOR pathway in MCF-7 cells. Guaraná decreased the colony formation and cell growth in MCF-7 and HT-29 cells. Guaraná did not affect normal cells. In conclusion, guaraná could be an important agent in antitumor pharmacologic therapies by inhibiting the mTOR and MAPKs pathways.